Connect with us

Press Releases

Nicox’s Licensee Bausch + Lomb Launches VYZULTA in Mexico

Its territories in Colombia, Hong Kong, Taiwan and Ukraine receives approval from the U.S. Food and Drug Administration.




(PRESS RELEASE) Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced that an affiliate of its licensee, Bausch + Lomb, has launched VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Mexico. Approval was obtained in Mexico in January 2020.

First approved by the U.S. Food and Drug Administration in late 2017, VYZULTA is now commercialized in the United States, Canada, Argentina and Mexico. It is also approved in 4 other territories — Colombia, Hong Kong, Taiwan and Ukraine — and is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Bausch Health Companies Inc. (NYSE/TSX: BHC) and its leading global eye health business, Bausch + Lomb, will continue seeking approvals in territories where the clinical data package, part of the U.S. New Drug Application, can be used for approval by the regulatory authorities.

Under the terms of the exclusive license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestones payments.



Transform Your Multi-office Phone System Into a Revenue-generation Tool

Weave’s multi-office, multi-department, and multi-provider phone system is built to flexibly accommodate and augment your practices’ most powerful revenue-generation tool: ring phones across multiple locations, set up inter-office call overflow, support external call centers, and more. And by connecting to your patient data, call handlers see a patient’s upcoming appointments, overdue balances, overdue family members, and preferred location – all when they pick up the phone." Learn more at

Promoted Headlines

Most Popular